Humanized HLA-G-0104 Biosimilar - Anti-HLA-G mAb - Research Grade
Source
HLA-G-0104, HLA-G-0031
Species
Humanized
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3 week if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
anti-HLA-G,HLAG,sHLA-G,HLA G antigen,MHC class I antigen G,HLA-6.0,HLA class I histocompatibility antigen,alpha chain G,HLA-G-0031,HLA-G-0104, HLA-G-0031
Reference
PX-TA1895
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1
Clonality
Monoclonal Antibody
Description of Humanized HLA-G-0104 Biosimilar - Anti-HLA-G mAb - Research Grade
Introduction
Humanized HLA-G-0104 Biosimilar, also known as Anti-HLA-G mAb, is a monoclonal antibody that is designed to target the human leukocyte antigen-G (HLA-G) protein. This biosimilar is a research grade antibody that has been developed to mimic the activity of the natural HLA-G protein and has potential therapeutic applications in various diseases.
Structure of Humanized HLA-G-0104 Biosimilar
Humanized HLA-G-0104 Biosimilar is a recombinant, humanized monoclonal antibody that is produced using recombinant DNA technology. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable regions are responsible for binding to the HLA-G protein, while the constant regions determine the antibody’s effector functions.
Activity of Humanized HLA-G-0104 Biosimilar
The main activity of Humanized HLA-G-0104 Biosimilar is to bind to the HLA-G protein, which is expressed on the surface of various cells, including immune cells, placental cells, and tumor cells. By binding to HLA-G, this biosimilar can modulate immune responses and regulate the function of immune cells.
One of the major functions of HLA-G is to induce immune tolerance, which is essential for maintaining a healthy pregnancy. Humanized HLA-G-0104 Biosimilar can mimic this function and has the potential to be used as a therapeutic agent in pregnancy-related complications, such as recurrent miscarriage and pre-eclampsia.
Moreover, HLA-G has been found to be overexpressed in various types of cancer, and its expression is associated with tumor progression and immune evasion. By targeting HLA-G, Humanized HLA-G-0104 Biosimilar can potentially inhibit tumor growth and enhance the anti-tumor immune response.
Application of Humanized HLA-G-0104 Biosimilar
Due to its ability to modulate immune responses, Humanized HLA-G-0104 Biosimilar has potential applications in various diseases, including pregnancy-related complications, cancer, and autoimmune diseases.
In pregnancy-related complications, this biosimilar can be used to prevent recurrent miscarriage, pre-eclampsia, and other pregnancy-related disorders by inducing immune tolerance and regulating the function of immune cells.
In cancer, Humanized HLA-G-0104 Biosimilar can be used as a therapeutic agent to inhibit tumor growth and enhance the anti-tumor immune response. It can also be used in combination with other cancer therapies to improve their efficacy.
In autoimmune diseases, HLA-G has been found to play a role in regulating immune responses and preventing autoimmune reactions. Humanized HLA-G-0104 Biosimilar can potentially be used to treat autoimmune diseases by modulating immune responses and reducing inflammation.
Conclusion
Humanized HLA-G-0104 Biosimilar, also known as Anti-HLA-G mAb, is a recombinant, humanized monoclonal antibody that targets the HLA-G protein. It has potential therapeutic applications in various diseases, including pregnancy-related complications, cancer, and autoimmune diseases. By mimicking the activity of the natural HLA-G protein, this biosimilar can modulate immune responses and regulate the function of immune cells. Further research and clinical trials are needed to fully understand the potential of Humanized HLA-G-0104 Biosimilar as a therapeutic agent.
Reviews
There are no reviews yet.